SCHOFIELD, Wis., May 11, 2009 (GLOBE NEWSWIRE) -- PuraMed Bioscience, Inc. (OTCBB:PMBS), a pharmaceutical company engaged in the development and marketing of a line of revolutionary, new, non-prescription medicines targeting major consumer health needs including the treatment of migraine headaches, insomnia and tension-type headaches announced today that they will be launching a series of 8 articles over as many weeks in the Wall Street Journal (WSJ) and the Investors Business Daily (IBD) newspaper publications.
Our primary objective in launching this marketing campaign is to draw the attention of U.S. consumers and potential investors to our organization and our suite of non-prescription drugs that are scheduled to hit the market in the third quarter of this calendar year. This marketing initiative will commence over the next 2 months, and management believes it will have a significant impact on how we are perceived by the investment community and by the public at large.
The first article will be published on May 11, 2009 in both the Wall Street Journal and the Investor Business Daily newspapers. Seven more articles will be published each successive Monday over a consecutive 8-week period. The first article will provide details on our initial three product offerings along with the benefits of our sublingual (under the tongue) dosing regiment which will offer us a serious competitive advantage. These articles can be found within the Corporate News section of both the WSJ and IBD newspapers. These articles can also be found on the websites of both the WSJ (2,870,000 newspaper and web readers) at http://online.wsj.com/home-page and the IBD website (1,692,000 newspaper and web readers) at http://www.investors.com/?tn=top.
These articles will also be published on the websites of Press Method at http://www.pressmethod.com/ and Equity Feed at http://www.equityfeed.com/, which are both popular websites dedicated to the individual and institutional investor. The combined viewership of these two sites is estimated at around 3,000,000 people on the internet.
The articles can also be found at GlobeNewswire at http://www.globenewswire.com/.
"Our initial products are complete and we are now in the process of implementing our initial go to market strategy of launching our products to the U.S. consumer via a direct response television commercial," said CEO Russell Mitchell. "We are extremely excited about this opportunity to tell our story to millions of potential investors as well as millions of consumers who can benefit from our revolutionary new products."
This news release contains forward-looking statements regarding PuraMed BioScience and its future business plans, which statements involve known and unknown risks and uncertainties. Such risks and uncertainties may cause actual results and future achievements of PuraMed BioScience to be materially different than those implied by these forward-looking statements. PuraMed BioScience has and undertakes no obligation to provide public updates and revisions to these forward-looking statements to reflect any changes in its expectations of future events.
The PuraMed BioScience Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=6155